EMD SERONO, INC

May 10, 2019

Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS

May 07, 2019

EMD Serono Launches MS-LINK(TM), a Community to Advance MS Science and Improve Patient Lives

Apr 30, 2019

EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019

Apr 08, 2019

MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts

Mar 29, 2019

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

Oct 31, 2018

EMD Serono Launches Community-Based Program to Advance Understanding of the Impact of Multiple Sclerosis on Patients and Caregivers

Oct 11, 2018

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis